You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Beyond Screen Time: Developing an objective mobile media measurement tool

    SBC: OpenLattice, Inc.            Topic: NICHD

    PROJECT ABSTRACT Excessive digital media use has been linked with several adverse health outcomes in childrenincluding obesitydisrupted sleepexternalizing behaviorand executive functioning deficitsbut measurement tools have not kept pace with the advancements in digital technology now used in most American householdsFor examplemost American families with young children now own a smartphoneor table ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Stem Cells for Treating Acute Stroke

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: 999

    ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Advance Early Detection of Lupus Nephritis with ClearGold

    SBC: CLEARNANO INC            Topic: 400

    SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Novel monoclonal antibody for single dose treatment of acute CNS injury

    SBC: OncoSynergy, Inc.            Topic: 999

    PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. STTR Phase I Development of Novel Antibacterial and Antifungal Bioadhesive Biomaterials for Diabetic Skin Wound Healing

    SBC: Dynamic Entropy Technology, LLC            Topic: NIDDK

    Abstract Diabetic ulcers or pressure ulcers are common for patients with diabetesspinal cord injuriesetcWithout proper managementsuch wounds often lead to infections such as osteomyelitis or sepsisresulting in high mortality and morbidityIn addition to bacterial infectiondiabetic patients are also more susceptible to cutaneous fungal infectionsAdvanced wound dressings and advanced wound therapies ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIAMS

    Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons

    SBC: SensoDX II, LLC            Topic: NIDA

    Abstract Opioid abuse disorder (OAD) affects 2.1 million of Americans annually resulting in overdoses numbering in the tens of thousands and skyrocketing rates of mortality. In addition to its enormous social impact, OAD carries a multi-billion-dollar price tag that includes $78.5 billion, specifically for health care and other costs related to prescription opioid abuse and misuse. Although effect ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Secure Homomorphically Encrypted National Registry of COVID-19 Recovered Plasma Donors

    SBC: ELIMU INFORMATICS, INC.            Topic: 172

    PROJECT SUMMARY Treatment with convalescent plasma (CP) was recently approved by the FDA for seriously ill patients of COVID-19. There are many institutions and hospitals that have implemented CP programs, but they all face the challenge of finding sufficient and appropriate donors. The constraints of matching, imbalances in supply and demand, and privacy concerns pose several challenges to engage ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: Lyst Therapeutics LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government